Investigational ABC transporter inhibitors

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 657-666

  Falasca, Marco ^a   Linton, Kenneth J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ABC transporters; Cancer chemotherapy; Cancer stem cells; Drug resistance; Drug targets; Transporter inhibitor

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG RESEARCH; HUMAN; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84859708410     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.679339     Document Type: Review

References (91)

1. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989-3011
2. ABC Proteins from Bacteria to Man. Elsevier Science Ltd.: Academic Press; London: 2003
3. Dean M. The Human ATP-Binding Cassette Transporter Superfamily. National Centre for Biotechnology Information; US: 2002
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73 (Pubitemid 19231814)
5. Inagaki N, Gonoi T, Clement JPT, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166-70
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58 (Pubitemid 37328807)
7. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34 (Pubitemid 43336035)
8. Gatti L, Cossa G, Beretta GL, et al. Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 2011;18:4237-49
9. The ABC Transporters of Human Physiology and Disease: Genetics and Biochemistry of ATP Binding Cassette Transporters. World Scientific, Singapore; 2011
10. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352-5 (Pubitemid 29369525)
11. Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118:671-82 (Pubitemid 351206556)
12. Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004;350:1296-303 (Pubitemid 38375364)
13. Harangi M, Kaminski WE, Fleck M, et al. Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjogren's syndrome. Eur J Immunol 2005;35:305-17 (Pubitemid 40136467)
14. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J 2001;357:859-65 (Pubitemid 32735167)
15. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33 (Pubitemid 36055335)
16. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-8 (Pubitemid 28507666)
17. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62 (Pubitemid 23335071)
18. Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996;271:1126-8 (Pubitemid 26075228)
19. Jardetzky O. Simple allosteric model for membrane pumps. Nature 1966;211:969-70
20. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004;19:216-24 (Pubitemid 39481937)
21. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918-26 (Pubitemid 39315294)
22. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9 (Pubitemid 17210152)
23. Martin C, Berridge G, Higgins CF, et al. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58:624-32
24. Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res 2006;12:3231-2
25. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4 (Pubitemid 23012438)
26. Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988-94 (Pubitemid 26065391)
27. Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994;54:4833-6 (Pubitemid 24289409)
28. Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005;131:355-63 (Pubitemid 40674620)
29. Mitra P, Oskeritzian CA, Payne SG, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103:16394-9. (Pubitemid 44715207)
30. Pineiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011;30:142-52
31. Yamada T, Mori Y, Hayashi R, et al. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 2003;63:895-901 (Pubitemid 36278415)
32. Konig J, Hartel M, Nies AT, et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005;115:359-67 (Pubitemid 40663738)
33. Henderson MJ, Haber M, Porro A, et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011;103:1236-51
34. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70 (Pubitemid 29018757)
35. Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896-902 (Pubitemid 39587528)
36. Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100:4594-601 (Pubitemid 35429703)
37. Chapuy B, Koch R, Radunski U, et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008;22:1576-86
38. Steinbach D, Gillet JP, Sauerbrey A, et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12:4357-63
39. van Waterschoot RA, Lagas JS, Wagenaar E, et al. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 2010;127:2959-64
40. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012;33:100-8
41. Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab 2011;12:722-31
42. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72 (Pubitemid 11114605)
43. Ozols RF, Cunnion RE, Klecker RW Jr, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7 (Pubitemid 17062504)
44. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996;32A:1070-81
45. Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011;12:570-94
46. Boesch D, Gaveriaux C, Jachez B, et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991;51:4226-33
47. Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830-8 (Pubitemid 43238450)
48. Baer MR, George SL, Dodge RK, et al. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32 (Pubitemid 34864276)
49. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8 (Pubitemid 29393559)
50. Germann UA, Ford PJ, Shlyakhter D, et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997;8:141-55 (Pubitemid 27102229)
51. Germann UA, Shlyakhter D, Mason VS, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997;8:125-40 (Pubitemid 27102228)
52. Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86:302-10 (Pubitemid 35425526)
53. Gandhi L, Harding MW, Neubauer M, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007;109:924-32 (Pubitemid 46333534)
54. Fracasso PM, Goldstein LJ, de Alwis DP, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004;10:7220-8 (Pubitemid 39487708)
55. Lancet JE, Baer MR, Duran GE, et al. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009;33:1055-61
56. Stewart A, Steiner J, Mellows G, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-91
57. Abraham J, Edgerly M, Wilson R, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 2009;15:3574-82
58. Shepard RL, Cao J, Starling JJ, et al. Modulation of P-glycoprotein but not MRP1-or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003;103:121-5 (Pubitemid 35424215)
59. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999;290:854-62 (Pubitemid 29344586)
60. Rubin EH, de Alwis DP, Pouliquen I, et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002;8:3710-17 (Pubitemid 35424760)
61. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004;10:3265-72 (Pubitemid 38685430)
62. Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569-80
63. Ruff P, Vorobiof DA, Jordaan JP, et al. A randomized, placebo-controlled, double-blind phase II study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009;64:763-8
64. Lancet JE, Baer MR, Duran GE, et al. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009;33:1055-61
65. Gekeler V, Ise W, Sanders KH, et al. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995;208:345-52
66. Turk D, Hall MD, Chu BF, et al. Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 2009;69:8293-301
67. Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009;4:7415
68. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53 (Pubitemid 46638777)
69. Burkhart CA, Watt F, Murray J, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009;69:6573-80
70. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010;5:597-615
71. Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004;11:1170-4 (Pubitemid 39117313)
72. Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26:258-68 (Pubitemid 46095736)
73. Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764
74. Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Update 2005;8:15-26 (Pubitemid 40797953)
75. Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-20 (Pubitemid 350145931)
76. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14
77. Nabekura T. Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins (Basel) 2010;2:1207-24
78. Chearwae W, Anuchapreeda S, Nandigama K, et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem Pharmacol 2004;68:2043-52 (Pubitemid 39346194)
79. Chen Z, Liu F, Ren Q, et al. Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 2010;126:841-51
80. Gillet JP, Gottesman MM. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 2011;12:686-92
81. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
82. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003;100:9244-9 (Pubitemid 37033914)
83. Leier I, Jedlitschky G, Buchholz U, et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269:27807-10 (Pubitemid 24354499)
84. Holla VR, Backlund MG, Yang P, et al. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008;1:93-9
85. Gatti L, Cossa G, Beretta GL, et al. Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 2011;18:4237-49
86. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84 (Pubitemid 40488633)
87. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010;86:631-7
88. Ahmed F, Arseni N, Glimm H, et al. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells 2008;26:810-18
89. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226-35
90. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009;30:546-56
91. Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 2011;108:18708-13